8-K: ARS Pharma Q2 2025: neffy Sales Surge, Global Expansion

ARS Pharmaceuticals reports strong second quarter 2025 financial results, driven by significant growth in neffy U.S. net product revenue and expanding global market access.

Summary

• Total revenue for the second quarter of 2025 was $15.7 million.
• neffy U.S. net product revenue reached $12.8 million in Q2 2025.
• Milestone revenue from ALK-Abell A/S (ALK) related to EURneffy launch in Germany was $2.6 million, part of a $5.0 million cash milestone.
• Research and Development (R&D) expenses were $4.0 million in Q2 2025.
• Selling, General and Administrative (SG&A) expenses were $54.3 million in Q2 2025, reflecting investment in a national direct-to-consumer (DTC) marketing campaign.
• Net loss for Q2 2025 was $44.9 million, or $0.46 per share.
• Cash, cash equivalents, and short-term investments totaled $240.1 million as of June 30, 2025.
• neffy two-pack unit weekly volumes increased approximately 180% from the end of Q1 2025 to the end of Q2 2025.
• Achieved 93% commercial coverage in the U.S., with 57% without prior authorization.
• Prior authorization approval rates for a portion of payors under Zinc (CVS Caremark GPO) are over 80%.
• Gross-to-net retention for Q2 2025 was 52%, reaching projected steady-state levels.
• Over 9,700 Healthcare Professionals (HCPs) have prescribed neffy to date, a 73% increase from April 2025.
• EURneffy was approved in the United Kingdom (U.K.) in July 2025 and successfully launched in Germany in June 2025.
• A Phase 2b clinical trial for neffy in urticaria was initiated in June 2025.

Sentiment

Score: 8

Explanation: The filing indicates very strong commercial momentum for neffy, with significant revenue growth, rapid increases in prescription volumes, and broad market access achieved ahead of expectations. Successful global expansion and the initiation of a new clinical program for urticaria further enhance future growth prospects. Despite the expected net loss due to strategic marketing investments, the overall performance and outlook are highly positive.

Positives

• Reported strong total revenue of $15.7 million for Q2 2025, driven by significant neffy U.S. net product revenue of $12.8 million.
• Achieved approximately 180% increase in neffy two-pack unit weekly volumes from the end of Q1 2025 to the end of Q2 2025.
• Secured 93% commercial coverage in the U.S., with 57% of coverage not requiring prior authorization, significantly reducing administrative barriers.
• Demonstrated high prior authorization approval rates, exceeding 80% for a portion of Zinc payers, indicating strong payer acceptance.
• Reached projected steady-state gross-to-net retention of 52% for Q2 2025, providing greater predictability for revenue modeling.
• Expanded HCP adoption with over 9,700 prescribers to date, a 73% increase from April 2025, with 70% being high-decile prescribers.
• Successfully launched EURneffy in Germany in June 2025, triggering a $5.0 million milestone payment from ALK.
• Received U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approval for EURneffy in July 2025, marking it as the first needle-free treatment in a major market outside the U.S.
• Initiated a Phase 2b clinical trial for intranasal epinephrine technology in urticaria, representing a significant opportunity to expand the product's utility to a new indication affecting approximately two million people in the U.S.
• Maintained a strong cash position of $240.1 million as of June 30, 2025, with guidance that financial position is expected to support operating plans for at least the next three years.
• The national DTC campaign significantly increased consumer awareness of neffy from a baseline of approximately 20% pre-campaign to 49% in late July.
• Expanded U.S. sales force reach through a co-promote partnership with ALK, targeting an additional 9,000 pediatricians.
• Over 3,200 schools have opted into the neffyinSchools program, receiving free doses for emergency use.

Negatives

• Reported a net loss of $44.9 million for the second quarter of 2025.
• Selling, General and Administrative (SG&A) expenses were substantial at $54.3 million, reflecting significant investment in marketing, which contributed to the net loss.
• Total cash, cash equivalents, and short-term investments decreased from $314.0 million at December 31, 2024, to $240.1 million at June 30, 2025, indicating a notable cash burn.

Risks

• Potential safety and other complications from neffy.
• Ability to maintain regulatory approval for neffy in its currently approved indications.
• The scope, progress, and expansion of developing and commercializing neffy.
• The scope, progress, and expansion of developing intranasal epinephrine technology.
• Clinical trial results may not be indicative of results that may be observed in the future.
• Potential for governments and payors to delay, limit, or deny coverage or reimbursements for neffy.
• The size and growth of the market for neffy and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products.
• Ability to protect intellectual property position.
• Impact of government laws, regulations, and policies.
• Reliance on licensing and co-promotion partners.
• Net product sales may not be indicative of profitability or profitability at expected levels.
• Reliance on survey results with small sample sizes.

Future Outlook

Financial position is expected to support operating plans for at least the next three years. Further neffy script momentum is anticipated in the second half of 2025 and beyond, driven by the DTC campaign. Gross-to-net retention is projected to remain at steady-state levels (around 50%). The company expects PBMs to continue reducing prior authorization requirements as neffy volume increases, positioning for continued market share growth and commercial expansion. EURneffy 2 mg product availability in the U.K. is expected in late second half of 2025, with EURneffy 1 mg EMA approval anticipated in the first half of 2026. Regulatory approvals for neffy in Canada, Japan, and Australia are expected by the end of 2025, with commercial rollouts planned for the first half of 2026. Regulatory approval for neffy in China is also expected in the first half of 2026. Topline data from the Phase 2b urticaria trial is anticipated in the first half of 2026, with potential for a pivotal trial, representing a significant market expansion opportunity.

Management Comments

• Richard Lowenthal, Co-Founder, President and CEO: "The second quarter marks a pivotal inflection point for neffy, highlighted by robust growth in prescriptions driven by expanding payor access and strong sales execution. As we move through the peak back-to-school prescribing season and with our most recent DTC investment and co-promote partnership, neffy is rapidly establishing itself as a preferred epinephrine option for patients, caregivers and schools. With continued commercial momentum in the U.S. and an expanded global presence marked by EURneffys approval in the U.K. and launch in Germany, we are advancing our vision to redefine the standard of care for allergic emergencies while creating lasting value for patients, providers and shareholders alike."
• Eric Karas, Chief Commercial Officer: "A key factor driving our growth and momentum has been achieving a critical milestone in payor access, which has significantly reduced administrative barriers for providers. As the volume of neffy continues to increase, we anticipate that the economic factors for the remaining PBMs will continue to reduce prior authorization requirements. Additionally, the combination of our sales force execution and DTC advertising further positions us for market share growth. This, along with a more seamless physician prescribing experience and enhanced consumer awareness, creates a strong foundation for continued commercial expansion."

Industry Context

neffy is positioned as the first and only FDA-approved and European Commission-approved needle-free epinephrine treatment, directly addressing significant unmet needs and limitations of traditional intramuscular auto-injectors, such as needle phobia, portability issues, and user error. The company is targeting a substantial U.S. market opportunity for Type I allergic reactions, estimated at over $3 billion in initial addressable segments and up to $7 billion in expansion segments. The market for epinephrine auto-injectors has shown consistent growth, with a +12.7% year-over-year increase in 2023. The strategic investment in a national direct-to-consumer marketing campaign and co-promote partnerships aims to capture significant market share by increasing patient and physician awareness and preference for a needle-free alternative. Furthermore, the expansion into the chronic spontaneous urticaria indication represents a new, large market opportunity, potentially adding another $2-3 billion in peak net sales.

Comparison to Industry Standards

• Prior authorization approval rates for neffy across major Pharmacy Benefit Managers (PBMs) are consistent with the overall epinephrine market, indicating competitive access.
• Dispensing rates by major PBMs for neffy are in line with the total epinephrine market, comparable to generic epinephrine auto-injectors (EAIs), despite some prior authorization requirements.
• The observed time-to-effect on prescriptions from the start of the DTC campaign (approximately 12-16 weeks) is consistent with historical trends for other pharmaceutical product launches.
• neffy's competitive co-pay of $25 for commercial patients is lower than the typical $40 co-pay for generic EAIs.
• neffy's 30-month shelf-life at room temperature, with up to 3 months at high temperatures (122°F), offers a competitive advantage in terms of product stability and usability.

Related Party Transactions

• Accounts payable and accrued liabilities included related party amounts of $1,091 thousand as of June 30, 2025, and $656 thousand as of December 31, 2024.
• Cost of goods sold included related party amounts of $866 thousand for the three months ended June 30, 2025, and $1,354 thousand for the six months ended June 30, 2025.
• Research and development expenses included related party amounts of $582 thousand for the three months ended June 30, 2025, and $1,245 thousand for the six months ended June 30, 2025.
• Selling, general and administrative expenses included related party amounts of $107 thousand for the three months ended June 30, 2025, and $231 thousand for the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders: Positive impact due to strong commercial growth, expanding market access, global approvals, and a solid cash runway, indicating potential for future revenue and value creation.
• Patients/Caregivers: Improved access to a needle-free epinephrine treatment (neffy), addressing limitations of traditional auto-injectors, potentially leading to better outcomes for allergic emergencies.
• Healthcare Providers (HCPs): Increased adoption and prescribing of neffy due to reduced administrative barriers (payor access), educational programs, and real-world experience opportunities.
• Employees: Continued investment in sales and marketing, and expansion into new indications, suggests job stability and growth opportunities.
• Partners (ALK, Alfresa, CSL, Pediatrix): Successful launches and anticipated approvals strengthen partnerships and generate milestone/royalty revenues.

Next Steps

• Further neffy script momentum is expected in the second half of 2025 and beyond.
• Continued investment in the ongoing promotion of neffy to further enhance patient and physician awareness and accelerate market share.
• EURneffy 2 mg product availability in the U.K. is expected beginning late in the second half of 2025.
• EURneffy 1 mg is undergoing regulatory review by the European Medicines Agency (EMA), with approval anticipated in the first half of 2026.
• Regulatory approvals for neffy in Canada, Japan, and Australia are expected by the end of 2025.
• Commercial rollouts for neffy in Canada, Japan, and Australia are planned for the first half of 2026.
• Regulatory approval for neffy in China is expected in the first half of 2026.
• Topline data from the Phase 2b clinical trial in urticaria is anticipated in the first half of 2026.
• Potential initiation of a pivotal trial for the treatment of acute flares in chronic spontaneous urticaria (CSU) patients on antihistamines.

Key Dates

Recommendation

The filing demonstrates exceptional commercial traction for neffy, with significant revenue growth, rapid increases in prescription volumes, and broad market access achieved ahead of expectations. The successful global expansion into the U.K. and Germany, coupled with a robust pipeline for additional international approvals and a new indication (urticaria), points to substantial future growth potential. Despite the current net loss, it is a result of strategic, aggressive investment in market penetration and awareness, which is yielding strong early returns. The company's strong cash position provides a long runway to execute its plans. This performance suggests a strong inflection point for the company, making it an attractive investment for long-term growth.

Keywords

neffy, epinephrine nasal spray, anaphylaxis, biopharmaceutical, allergic reactions, FDA approval, commercial launch, Q2 2025 results, SPRY, drug development, pharmaceutical sales, market access, urticaria, needle-free